Monthly Archives: August 2009

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic hardships, given the direct health and indirect economic benefits of biotechnology research, will governments sustain, increase, or decrease their R&D budgets?

The impact of the global financial crisis on biotechnology development